CAC Software vs ElucidVivo A.3

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 70/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

CAC Software

by 4DMedical (Imbio CAC Software)

ElucidVivo A.3

by Elucid

AI Verdict

Tool A specializes in quantifying coronary artery calcification from non-contrast CT scans to assess cardiac risk. Tool B provides a more comprehensive analysis of arterial plaque composition and stability, including calcifications, from CT angiography, aiding in detailed atherosclerosis patient stratification and treatment optimization. While both contribute to cardiovascular disease assessment, Tool A focuses narrowly on calcification, whereas Tool B offers broader plaque characterization.

Choose CAC Software if…

Choose Imbio's CAC Software if your primary objective is to quickly and accurately quantify coronary artery calcification from existing non-contrast chest CT scans for initial cardiovascular risk assessment. This tool is ideal for identifying patients at risk of coronary artery disease by providing an Agatston score and other calcification metrics, integrating seamlessly into your current DICOM workflow.

View CAC Software →

Choose ElucidVivo A.3 if…

Choose ElucidVivo A.3 if you require a detailed, quantitative analysis of arterial plaque composition and stability from CT angiography to stratify atherosclerosis patients and optimize treatment decisions. This system excels at visualizing and measuring specific plaque characteristics, such as Lipid-Rich Necrotic Core, and can derive fractional flow reserve (FFRct) to provide a comprehensive understanding beyond simple calcification.

View ElucidVivo A.3 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	CAC Software	ElucidVivo A.3
Deployment	Cloud-based (SaaS), integrates with PACS	Cloud and on-premise secure deployment.
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	CAC Software	ElucidVivo A.3
Name	CAC Software	ElucidVivo A.3
Company	Imbio	Elucid Bioimaging
Primary Analysis Focus	Automated image post-processing for coronary artery calcification, determining location and calculating amount of calcification.	Quantitative analysis of arterial plaque composition and stability.
Key Output Metrics/Quantifications	Agatston score, arterial age, calcified lesion mass and volume	Quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications; derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity.
Visualization Capabilities	3D visualizations and annotated images	Detailed visualization of plaque characteristics, 3D visualization of highlighted vessels, rotatable curved MPR vessel views and cross-sections.
Input Scan Type	Non-contrast, chest computed tomography (CT)	CT angiography

Videos

Demos, reviews, and walkthroughs featuring CAC Software and ElucidVivo A.3.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What type of imaging study is required for each tool?

Imbio's Coronary Artery Calcification (CAC) software is designed to analyze non-contrast chest computed tomography (CT) scans to evaluate coronary artery calcification. ElucidVivo A.3 by Elucid Bioimaging, on the other hand, performs quantitative analysis of arterial plaque composition and stability from CT angiography.

What specific clinical insights and metrics do these tools provide?

Imbio's CAC software quantifies calcification within the coronary arteries, providing outputs such as the Agatston score, arterial age, calcified lesion mass, and volume to support risk assessment for coronary artery disease. ElucidVivo A.3 offers detailed visualization and measurement of arterial plaque characteristics, objectively quantifying Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications, and derives fractional flow reserve (FFRct) to aid in atherosclerosis patient stratification and treatment decisions.

How do these tools assist in patient management and decision-making?

Imbio's CAC software supports risk assessment for coronary artery disease by providing a quantification of coronary artery calcification. ElucidVivo A.3 assists physicians in atherosclerosis patient stratification and optimizes treatment decisions by offering detailed analysis of plaque composition and stability, validated against histology.

What are the differences in regulatory clearance and compliance?

Both Imbio's CAC software and ElucidVivo A.3 are FDA-cleared. Imbio's CAC software explicitly states it is HIPAA compliant and offers a Business Associate Agreement (BAA). For ElucidVivo A.3, HIPAA compliance and BAA availability are not explicitly stated, but implied by its FDA clearance and intended use in the U.S. healthcare system.

Is there any information on the validation of the analysis provided by these tools?

ElucidVivo A.3 explicitly states that its detailed visualization and measurement of plaque characteristics are validated against histology. The provided information for Imbio's CAC software does not explicitly detail its validation methodology, though it uses deep-learning based analysis.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform